Next Article in Journal
Next Article in Special Issue
Previous Article in Journal
Previous Article in Special Issue
Pharmaceuticals 2010, 3(8), 2610-2646; doi:10.3390/ph3082610

Pharmacogenetics of Anti-Diabetes Drugs

1,*  and 2
Received: 14 July 2010; in revised form: 9 August 2010 / Accepted: 10 August 2010 / Published: 13 August 2010
(This article belongs to the Special Issue Antidiabetic Drugs)
View Full-Text   |   Download PDF [237 KB, uploaded 13 August 2010]
Abstract: A variety of treatment modalities exist for individuals with type 2 diabetes mellitus (T2D). In addition to dietary and physical activity interventions, T2D is also treated pharmacologically with nine major classes of approved drugs. These medications include insulin and its analogues, sulfonylureas, biguanides, thiazolidinediones (TZDs), meglitinides, α-glucosidase inhibitors, amylin analogues, incretin hormone mimetics, and dipeptidyl peptidase 4 (DPP4) inhibitors. Pharmacological treatment strategies for T2D are typically based on efficacy, yet favorable responses to such therapeutics are oftentimes variable and difficult to predict. Characterization of drug response is expected to substantially enhance our ability to provide patients with the most effective treatment strategy given their individual backgrounds, yet pharmacogenetic study of diabetes medications is still in its infancy. To date, major pharmacogenetic studies have focused on response to sulfonylureas, biguanides, and TZDs. Here, we provide a comprehensive review of pharmacogenetics investigations of these specific anti-diabetes medications. We focus not only on the results of these studies, but also on how experimental design, study sample issues, and definition of ‘response’ can significantly impact our interpretation of findings. Understanding the pharmacogenetics of anti-diabetes medications will provide critical baseline information for the development and implementation of genetic screening into therapeutic decision making, and lay the foundation for “individualized medicine” for patients with T2D.
Keywords: pharmacogenetics; biguanides; sufonylureas; thiazolidinediones; type 2 diabetes mellitus; drug response; association analysis; candidate gene pharmacogenetics; biguanides; sufonylureas; thiazolidinediones; type 2 diabetes mellitus; drug response; association analysis; candidate gene
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |

MDPI and ACS Style

DiStefano, J.K.; Watanabe, R.M. Pharmacogenetics of Anti-Diabetes Drugs. Pharmaceuticals 2010, 3, 2610-2646.

AMA Style

DiStefano JK, Watanabe RM. Pharmacogenetics of Anti-Diabetes Drugs. Pharmaceuticals. 2010; 3(8):2610-2646.

Chicago/Turabian Style

DiStefano, Johanna K.; Watanabe, Richard M. 2010. "Pharmacogenetics of Anti-Diabetes Drugs." Pharmaceuticals 3, no. 8: 2610-2646.

Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert